MARKET

CLBS

CLBS

Caladrius
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.710
-0.060
-2.17%
Closed 16:00 11/15 EST
OPEN
2.770
PREV CLOSE
2.770
HIGH
2.830
LOW
2.630
VOLUME
40.01K
TURNOVER
--
52 WEEK HIGH
5.44
52 WEEK LOW
2.000
MARKET CAP
28.18M
P/E (TTM)
-1.5384
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CLBS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CLBS News

  • Edited Transcript of CLBS earnings conference call or presentation 6-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.1d ago
  • Caladrius Biosciences Reports Positive Results for CLBS16 from the ESCaPE-CMD Trial at AHA Scientific Sessions
  • Benzinga.1d ago
  • Caladrius Biosciences Reports Positive Results for CLBS16 from the ESCaPE-CMD Trial at American Heart Association Scientific Sessions 2019
  • GlobeNewswire.1d ago
  • The Week Ahead In Biotech: Adcom Test For Amarin's Fish Oil Pill, Agile Awaits FDA Verdict
  • Benzinga.11/10 21:08

More

Industry

Biotechnology & Medical Research
+1.25%
Pharmaceuticals & Medical Research
+1.34%

Hot Stocks

Name
Price
%Change

About CLBS

Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company's lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient's own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.
More

Webull offers Caladrius Biosciences Inc (CLBS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.